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A b s t r a c t  
This investigation concerns the development of sustained released floating matrix tablets of 
Baclofen for improving its bioavailability by prolonging gastric residence time. Floating matrix tablets 
(FMT) of Baclofen were prepared using 32 optimization designs.Carbopol 934p, HPMC K4M and 
gas generating agents such as sodium bicarbonate and citric acid were used in formulation. The 
fabricated tablets were evaluated for their physical characteristics such as hardness, drug content, 
buoyancy, swelling properties and in vitro release studies in 0.1N HCl. The tablets without gas 
generating agents and HPMC K4M did not float at all. Tablets with gas generating agents and 
HPMC K4M and Carbopol 934p floated up to 12 h without complete erosion and showed slower 
drug release. HPMC K4M and Carbopol 934P maintain the integrity of the FMT and sustaining the 
drug release. The increase in the concentration of HPMC K4M and Carbopol 934p in FMT from 75 
mg to 125 mg and 20 mg to 60mg respectively resulted in decrease in release rate of drug. The 
possibility of drug polymer interaction was determined by differential scanning calorimetric (DSC) 
and Fourier transform infrared (FTIR) spectrometer, and confirmed no interaction between drug and 
polymers. The mechanism of drug release is mainly described by diffusion and swelling mechanism 
of polymers.  
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Introduction 
Oral delivery of drugs is by far the most preferred route of drug 
delivery, due to ease of administration, patient compliance and 
flexibility in formulation. Conventional immediate oral dosage forms 
provides a specific drug concentration in the systemic circulation 
with limited control over drug delivery. Controlled-release drug 
delivery systems provide drug release at a predetermined, 
predictable rate and optimize the therapeutic effect of a drug by 
controlling its release in the body with lower and less frequent 
doses 
A major constraint in oral controlled drug delivery is that most of 
the drug candidates are not absorbed uniformly throughout the 
gastrointestinal tract. Some drugs are absorbed only in a particular 
region of the GIT or are absorbed to a different extent in various 
segments of the GIT and are said to have an Âabsorption windowÊ 
which identifies the primary region of absorption of the drug in the 
GIT because of physiological, physicochemical or biochemical 
factors. 1, 2, 3 
Dosage forms that can be retained in the stomach are called gastro 
retentive drug delivery systems. Gastro retentive drug delivery 
system can improve controlled delivery of drugs with an absorption 
window by continuously releasing the drug for a prolonged period 
before it reaches its absorption site, thus ensuring optimal 
bioavailability. 6 
Materials and methods 
Materials  
Baclofen was procured from Watson Pharma Goa; HPMC K4M 
was procured from Colorcon, Goa. All other chemicals used were 
of analytical grade. 
Experimental design 
To optimize the formulation the 32 design was implemented. The 
independent variables were amount of Carbopol 934 (mg) (X1) and 
amount of HPMC K4M (mg) (X2). The dependent variables 
(responses) were drug release in 4 hrs (%) (Y1), drug release in 8 
hrs (%) (Y2) and drug release in 12 hrs (%) (Y3). The independent 
and dependent variables and the used levels are summarized in  
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Preparation of sustained released floating matrix tablets  
The corresponding amount of drug, HPMC K4M, Carbopol 934, 
magnesium stearate, 
sodium CMC, sodium bicarbonate, citric acid were accurately 
weighed. The powders 
were screened through screen #60.The screened powders were 
transferred to mortar 
and mixed for 20 minutes. After addition of lubricant and glidant 
(Mg Stearate) 
compression was carried out using 10 mm flat-faced circular 
punches on rotary 
compression machine (general machineries). Hardness was 
maintained between 3-6 Kg/cm2.[5-10] 
Floating properties  
The time the tablets took to emerge on the water surface (floating 
lag time) and the time the tablets constantly float on the water 
surface (duration of floating) were evaluated in dissolution vessel 
(dissolution tester) filled with 500ml of artificial gastric fluid without 
pepsin, pH 1.2; T= 37ĈC μ 0.5, paddle rotation= 100 rpm. The 
measurement is carried out for each series of tablets (n=9) 11 
Drug release testing  
The release rate of Baclofen from floating tablets was determined 
using USP DissolutionTesting Apparatus II (Paddle type). The 
dissolution test was performed using 900 ml of PH 1.2 Buffer, at 37 
μ 0.5ĈC with 50 rpm. Aliquot (5 ml) of the solution was collected 
from the dissolution apparatus hourly for 12 hrs and were replaced 
with fresh dissolution medium. The aliquots were filtered through 
filter paper. Absorbance of these solutionswas measured at 264 
nm. Cumulative percentage drug release was calculated. Analysis 
of data was done by using PCP Disso V-3 software and Microsoft 
excel. 12 
 
 
Result and discussion  
The development of matrix floating tablet 
On the basis of prior studies on the floating properties of matrix 
tablets, we conclude that the hydroxypropylmethyl cellulose K4M 
polymer is the best vehicle for the floating tablets design. 
(Baumgartner et al; 1998).13 The floating properties of the tablet 
are, however, expected to be altered when a high dose of the 
active component is incorporated. Tablets with different ratios of 
the drugs versus polymer were prepared to optimize the drug 
content and floating properties. It was determine that besides the 
tablet composition, the tablet hardness has an essential role for 
floating properties.  
 Physicochemical characteristics of tablets  
 Swelling indices16 
 Drug release study  
 To study the release kinetics, the in-vitro dissolution drug release 
data of formulations applied to various kinetic models viz. zero 
order, first order, Higuchi  and Korsmeyer-Peppas equation.      
Results were shown in fig  
The release constant was calculated from the slope of the 
appropriate plots and the regression coefficient (R2) was 
determined.[14,15] 
The corresponding plot for the Korsmeyer-Peppas equation 
indicated a good linearity (R2). The mechanism of drug release is 
mainly described by diffusion and swelling mechanism of polymers.  
 Mathematical modeling and release kinetics of Baclofen from the 
prepared floating tablets. 
Experimental design & factorial design 17, 18 
The mathematical model of the effects of independent variables 
upon the dependent variables was performed using stat-ease 
design expert (version 7.1.6) with a manual linear regression 
technique. Significant terms (p < 0.05) were chosen for final 
equations. Finally Response surface plots resulting from equations 
were drawn.  
Y = b 0 + b 1 X 1 + b 2 X 2 + b 12 X 1 X 2 + b 11 X 1 2 + b 22 X 22 
⁄⁄⁄⁄⁄⁄(1)                                         
Where, Y is the dependent variable, b0 is the arithmetic mean 
response of the 9 runs and bi (b1, b2, b12, b11 and b22) is the 
estimated coefficient for the corresponding factor Xi (X1, X2, X1X2, 
X12 and X22), which represents the average result of changing 1 
factor at a time from its low to high value. The interaction term 
(X1X2) shows how the response changes when 2 factors are 
simultaneously changed. The polynomial terms (X12 and X22) are 
included to investigate nonlinearity. All 9 batches of design has 
shown wide variation in % drug release in 4 hours (23.06-55.78), 8 
hours (47.62-89.09) 12 hours (88.1-111.77)  The fitted equations 
relating the response Y1 and Y2   & Y3 to the transformed factor are 
shown in equation-2 and equation -3 respectively.  
i) Final Equation in Terms of Coded Factors: (for 1st approach) 
Release in 4 hrs  = +37.17 + 3.35* A - 12.06* B - 2.46*A* B⁄⁄ (2) 
Factors 
(independent 
variables) 
 Levels 
used 
 Responses 
(dependent 
variables) 1 0 -1 
X1 = amount of  
Carbopol 934 (mg) 
20 40 60 Y1 = drug 
release in 4 
hrs (%) 
X2 = amount of 
HPMC K4M (mg) 
75 100 125 Y2 = drug 
release in 8 
hrs (%) 
Y3 = drug 
release in 12 
hrs (%) 
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ii) Final Equation in Terms of Actual Factors 
Release in 4 hrs  = + 58.99444 + 0.66067 *Carbopol 934 - 0.28527 
* HPMC K4M -4.93 * Carbopol 934 * HPMC K4M⁄⁄⁄⁄.. (3) 
iii)Final Equation in Terms of Coded Factors 
Drug release in 8 hrs  = + 64.28 - 9.21* A - 8.72* B + 6.83 * A * 
B⁄⁄.. (4) 
d) Final Equation in Terms of Actual Factors 
 Release in 8 hrs = +172.27111 - 1.82767 * Carbopol 934 - 
0.89560 * HPMC K4M+0.013670 * Carbopol 934 * HPMC 
K4M⁄⁄.. (5) 
iv) Final Equation in Terms of Coded Factors 
Release in 12 hrs = +89.14 - 2.03 * A - 5.04* B+6.47 * A * B+3.58* 
A2+6.33* B2⁄⁄.. (6) 
v) Final Equation in Terms of Actual Factors 
Release in 12 hrs  = +280.68556 - 2.11175 * Carbopol 934 -
2.74387  * HPMC K4M+0.012940* Carbopol 934 * HPMC 
K4M+8.95417E-003 *Carbopol 9342+0.010123* HPMC K4M2 
⁄⁄.. (7) 
Drug release of formulations at 4, 8 & 12 hrs17, 18, 19 
Surface and contour plots for 4, 8, & 12hours respectively 
ANOVA for Response Surface Model: 
Response 1-Drug release in 4 hours 
 ANOVA for Response Surface 2FI Model: 
Response 2-Drug release in 8 hours 
 ANOVA for Response Surface 2FI Model 
Response 3-Drug release in 12 hours 
ANOVA for Response Surface Quadratic Model 
 
Table No ă 1- Formulation quantities 
 
 
 
 
 
 
 
 
 
Table No- 2 - Physicochemical characteristics of tablets 
 
Formulation 
code 
Tablet 
thickness 
(mm) 
Tablet weight
(mg) 
Drug content
(%) 
Tablet 
friability 
(%) 
Floating 
lag 
time (s) 
Total 
floating 
duration (h) 
F1 4.92μ0.05 262.48 μ2.74 95.5μ0.92 0.24μ0.10 70μ1.23 > 12 
F2 5.12μ0.05 282.06 μ4.37 96.8μ0.34 0.36μ0.08 88μ1.52 > 12 
F3 4.95μ0.05 313.31 μ5.70 96μ0.55 0.45μ0.12 55μ1.09 > 12 
F4 5.14μ0.05 277.28 μ2.97 99μ1.05 0.51μ0.10 100μ1.80 > 12 
F5 4.96μ0.05 315.00 μ5.11 97.5μ0.88 0.48μ0.04 80μ1.20 > 12 
F6 4.98μ0.05 335.73μ3.33 98.6μ0.98 0.49μ0.07 58μ1.05 > 12 
F7 5.05μ0.05 311.27μ3.53 97μ0.70 0.46μ0.05 80μ1.09 > 12 
F8 5.10μ0.05 333.85μ3.05 96μ0.87 0.52μ0.08 65μ1.25 > 12 
F9 4.94μ0.05 357.74μ2.12 97μ1.08 0.55μ0.15 120μ2.1 > 12 
 
 
 Quantities in milligram
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Drug 75 75 75 75 75 75 75 75 75
HPMC K4M 75 100 125 75 100 125 75 100 125
Carbopol 934 20 20 20 40 40 40 60 60 60
Sodium bicarbonate 50 50 50 50 50 50 50 50 50
Citric acid 25 25 25 25 25 25 25 25 25
Magnesium stearate 5 5 5 5 5 5 5 5 5
Sodium CMC 20 20 20 20 20 20 20 20 20
Total weight 270 295 320 290 315 340 310 335 360
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Table No- 3 ă Release kinetics of baclofen 
 
Formulacod
e 
Zero-order 
plots 
Correlation 
coefficient 
(R2) 
1st  order 
plots 
Correlation 
coefficient 
(R2) 
HiguchiÊs plots 
Correlation 
coefficient 
(R2) 
Korsmeyeră
Peppas plots 
Correlation 
coefficient 
(R2) 
Diffusional 
exponent 
(n) 
Order of
release 
F1 0.98 0.98 0.98 0.98 0.88 Non ă fickian 
transport 
F2 0.98 0.98 0.95 0.99 1.08 Super case 2 
transport 
F3 0.98 0.98 0.92 0.99 1.3 Super case 2 
transport 
F4 0.97 0.97 0.99 0.98 0.60 Non ă fickian 
transport 
F5 0.99 0.99 0.94 0.99 0.76 Non ă fickian 
transport 
F6 0.98 0.98 0.92 0.98 1.009 Super case 2 
transport 
F7 0.93 0.93 0.93 0.74 0.43 Non ă fickian 
transport 
F8 0.95 0.95 0.90 0.84 0.69 Non ă fickian 
transport 
F9 0.98 0.98 0.92 0.99 1.19 Super case 2 
transport 
 
Table No- 4- Drug release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbopol 934 
(mg) 
HPMC 
K4M (mg) 
Drug release in (%) 4 
hrs 
Drug release 
in 
(%) 8 hrs 
Drug release 
in (%)12 hrs 
20 75 43.22 89.09 111.77 
20 100 33.33 72.32 96.31 
20 125 23.06 61.53 88.83 
40 75 49.12 74.72 100.08 
40 100 39.18 63.06 90.18 
40 125 26.93 50.18 89.82 
60 75 55.78 60.13 96.85 
60 100 38.19 47.62 88.1 
60 125 25.76 59.91 99.79 
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Table No. 5: Analysis of variance table for 4 hours [Partial sum of squares - Type III] 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No. 6:Analysis of variance table for 8 hours [Partial sum of squares - Type III] 
Source Sum of Squares df Mean
Square 
F
Value 
p-value 
Prob > F 
Significant or
Non-  
significant 
Model 1152.412 3 384.1375 12.11831 0.0099 Significant 
A-Carbopol 
934 509.3131 1 509.3131 16.0672 0.0102 
 
- 
B-HPMC K4M 456.2304 1 456.2304 14.39261 0.0127 
- 
 
AB 186.8689 1 186.8689 5.895117 0.0595 - 
Residual 158.4947 5 31.69893 - - - 
Core Total 1310.907 8 - - - - 
 
Table No. 7: Analysis of variance table for 12 hours [Partial sum of squares - Type III] 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source 
Sum of Squares df Mean Square F Value P value 
Prob > F 
Significant or
Non-  
significant 
Model 964.6768 3 321.5589 107.0148 < 0.0001 Significant
A-Carbopol 
934 67.46907 1 67.46907 22.4537 0.0052 
Significant
B-HPMC K4M 872.9028 1 872.9028 290.502 < 0.0001 Significant
AB 24.3049 1 24.3049 8.08867 0.0361 Significant
Residual 15.02404 5 3.004808 - - - 
Core Total 979.7008 8 - - - - 
Source Sum of Squares df Mean
Square 
F
Value 
p-value
Prob > F 
Significant or
Non-  
significant 
Model 450.4498 5 90.08996 17.56895 450.4498 significant
  A-Carbopol 
934 24.68482 1 24.68482 4.813927 24.68482 
 
         - 
  B-HPMC 
K4M 152.6113 1 152.6113 29.76159 152.6113 
 
      - 
  AB 167.4436 1 167.4436 32.65413 167.4436       - 
  A^2 25.65667 1 25.65667 5.003454 25.65667       - 
  B^2 80.05342 1 80.05342 15.61167 80.05342       - 
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Fig. No. 2: Zero order drug release graph 
    
 
 
Fig. No. 3: First order drug release graph 
 
 
 
 
Fig. No. 4: Higuchi model drug release graph 
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Fig. No. 5: Korsmeyer Peppas model drug release graph 
 
 
 
Fig. No. 6: Contour plot for 4 hours drug release 
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Fig. No. 7: Surface response plot for 4 hours drug release 
 
 
Fig. No. 8: Contour plot for 8 hours drug release 
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Fig. No. 9: Surface response plot for 8 hours drug release 
 
 
 
 
Fig. No. 10: Contour plot for 12 hours drug release 
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 Fig. No. 11: Surface response plot for 12 hours drug release 
Conclusion  
An oral sustained released dosage form offer many advantages for 
drugs having absorption from the upper gastrointestinal tract and 
improves the bioavailability of medications that are characterized 
by the narrow absorption window. A Gastro retentive sustained 
released floating matrix tablets was developed with polymers like 
HPMC (K4 M), Carbopol (934P) & effervescent mixture (sodium 
bicarbonate & citric acid) with floating and swellable properties. 
Where the polymers act as a release retarding agent and the 
effervescent mixture aid for floatation. 
As the concentration of the polymers increases the swelling 
properties goes on increasing as well as the release rate  
 
 
decreased. The optimized formulation followed Korsmeyer-Peppas 
kinetics, while the drug release mechanism was found to be of non-
fickian type (diffusion & swelling type of drug release).  
Hence the formulated systems F4 have better bioavailability of drug 
due to increase gastric residence time. Because floating tablets 
remains float in stomach reason due to this absorption of window 
increases and hence the bioavailability of formulation code F4 
increased 
 
 
 
 
References  
[1]. Ritesh Kumar, Anil Philip, 
Gastroretentive Dosage Forms for 
Prolonging Gastric Residence Time, 
Int J Pharm Med 2007; 21 (2): 157-
171. 
[2]. Aulton, ME, editor, The 
gastrointestinal tract physiology and 
drug absorption, Pharmaceutics: the 
science of dosage form design. 2nd 
ed. New, York: Churchill 
Livingstone, 2002: 217-27. 
[3]. Gupta PK, Robinson JR. Oral 
controlled-release delivery, Treatise 
on controlled drug delivery, New 
York: Marcel Dekker, 1992: 255-
310. 
[4]. International Journal of 
Pharmaceutical Sciences Review 
and Research, Volume 2, Issue 2, 
May ă June 2010; Article 014, an 
overview on various approaches to 
oral controlled drug delivery system 
via Gastroretention. 
[5]. Mirza S, Miroshnyk I, Rantanen J, 
Aaltonen J, Harjula P, Kiljunen E,  
Heinamaki J, Yliruusi J, Solid State 
Properties And Relationship 
between Anhydrate and 
Monohydrate of Baclo, fen, Journal 
of Pharmaceutical Sciences, 
96(9),September (2007), P 2399-
2408. 
[6]. Khan F, Razzak SM, Khan ZR, Kazi  
Khan  RK, Anowar Sadat SM and  
Raza S, Preparation And invitro 
Evaluation Of Theophylline Loaded 
Gastroretentive Floating Tablets Of 
Methocel K4M, Dhaka Univ. J. 
Pharm. Sci. 7(1) P  65-70, (2008) 
June. 
Kakad et al. International Journal of Drug Delivery 4 (4) 443-454 [2012] 
 
PAGE | 454 |
 
 
[7]. Janardhan D, Lingam M, Mohan CK 
and Venkateswarlu V, Formulation 
and in vitro evaluation of 
gastroretentive drug delivery system 
for Ranitidine hydrochloride, 
International journal of 
pharmaceutical sciences and 
nanotechnology, 1(3), October-
December (2008), P-227-232. 
[8].  Patel R, Baria A, Formulation 
development and process 
optimization of Theophylline 
sustained release matrix tablets, 
International journal of  pharmacy 
and pharmaceutical sciences, 1(2), 
October-December (2009), P-30-42. 
[9]. Pare A, Yadav SK and Patil UK, 
Formulation and Evaluation of 
Effervescent Floating Tablet of 
Amlodipine besylate, Research J. 
Pharm. and Tech. 1(4): Oct.-Dec. 
(2008), P- 526-530. 
[10]. Raju DB, Sreenivas R and Varma 
MM, Formulation and evaluation of 
floating drug delivery system of 
Metformin Hydrochloride, Journal of 
Chemical and Pharmaceutical 
Research, J. Chem. Pharm. Res, 
(2010), 2(2) P 274-278. 
[11]. Arunkumar N, Rani C and Mohanraj 
KP, Formulation and in vitro 
evaluation of oral floating tablets of 
atorvastatin calcium, Research J. 
Pharm. and Tech. 1(4): Oct-Dec 
(2008), P 492-495. 
[12]. The United State Pharmacopoeia, 
2004, twenty seventh, revision and 
The National Formulary, twenty two 
Edition, The Official Compendia of 
Standards, Asian Edition, Published 
by The Board Of Trustees, P 776 -
777. 
[13]. Baumgartner, S., S_mid-Korbar, J., 
Vrecer, F., Kristl, J., 1998. Physical 
and technologica parameters 
influencing floating properties of 
matrix tablets based on cellulose 
ethers. S.T.P. Pharma Sci. 8, 182ă
187. 
[14]. Lachman, L, Liberman, HA, Kanig, 
J. L, (1990), The Theory and 
Practice of Industrial Pharmacy, 
Varghese publishing house third 
edition, P 296-302. 
[15]. Arunkumar N, Rani C and Mohanraj 
KP, Formulation and in vitro 
evaluation of oral floating tablets of 
atorvastatin calcium, Research J. 
Pharm. and Tech. 1(4): Oct-Dec 
(2008), P 492-495. 
[16]. Anilkumar J, Shinde AN, Waghule 
MB, Paithane, More HN, 
Formulation And in vitro Evaluation 
Of Sustained Release Floating 
Tablet Of Cephalexin Using 
Hydrophilic Polymers, International 
Journal Of Pharmacy and 
Pharmaceutical Sciences,  2(2), 
(2010), P-58-65. 
[17]. Prajapati1 ST, Patel LD and Patel 
CN, Floating matrix tablets of 
domperidone: formulation and 
optimization using simplex lattice 
design, Thai J. Pharm. Sci. 33 
(2009) P 113-122. 
[18]. Mohapatra S, Kar RK, Barik BB, 
Formulations and Statistical 
Optimization of Intra Gastric Floating 
Matrix Tablets of Cefuroxime Axetil, 
Journal of Pharmacy Research 2(3), 
March (2009), P 545-550. 
[19]. Monica RP, Girish SS, Rachana 
RM, Swapnali DV, Evaluation Of 
Effervescent Floating Matrix Tablet 
Formulations Of Salbutamol Sulfate 
Using Full Factorial Design, Asian 
Journal Of  Pharmaceutics, Jan- 
March (2009), P 43-49. 
 
 
 
 
 
